BHF Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, UK.
BHF Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, UK; Mass Spectrometry Core, Edinburgh Clinical Research Facility, Queen's Medical Research Institute, University of Edinburgh, UK.
Metabolism. 2022 Mar;128:155118. doi: 10.1016/j.metabol.2021.155118. Epub 2022 Jan 4.
Cortisol and corticosterone both circulate in human plasma and, due to differing export by ATP-binding cassette (ABC) transporters, may exert differential cellular effects. ABCB1 (expressed in brain) exports cortisol not corticosterone while ABCC1 (expressed in adipose and skeletal muscle) exports corticosterone not cortisol. We hypothesised that ABCC1 inhibition increases corticosteroid receptor occupancy by corticosterone but not cortisol in humans.
A randomised double-blind crossover study was conducted in 14 healthy men comparing placebo and ABCC1 inhibitor probenecid. Blood sampling, including from veins draining adipose and muscle, was undertaken before and after administration of mineralocorticoid receptor antagonist potassium canrenoate and glucocorticoid receptor antagonist mifepristone (RU486).
During placebo, systemic plasma cortisol and corticosterone concentrations increased promptly after canrenoate. Cortisol uptake was detected from adipose but not muscle following canrenoate + RU486. Probenecid significantly increased systemic cortisol concentrations, and tended to increase corticosterone and ACTH concentrations, after combined receptor antagonism but had no effects on net glucocorticoid balance in either adipose or muscle. Using quantitative PCR in brain bank tissue, ABCC1 expression was 5-fold higher in human pituitary than hypothalamus and hippocampus. ABCB1 was more highly expressed in hypothalamus compared to pituitary.
Although displacement of corticosterone and/or cortisol from receptors in adipose and skeletal muscle could not be measured with sufficient precision to detect effects of probenecid, ABCC1 inhibition induced a greater incremental activation of the hypothalamic-pituitary-adrenal axis after combined receptor blockade, consistent with ABCC1 exporting corticosterone from the pituitary and adding to the evidence that ABC transporters modulate tissue glucocorticoid sensitivity.
皮质醇和皮质酮都在人体血浆中循环,由于不同的三磷酸腺苷结合盒(ABC)转运蛋白的输出,可能产生不同的细胞效应。ABCB1(在大脑中表达)输出皮质醇而非皮质酮,而 ABCC1(在脂肪和骨骼肌中表达)输出皮质酮而非皮质醇。我们假设 ABCC1 抑制增加了皮质酮而不是皮质醇对人类糖皮质激素受体的占据。
在 14 名健康男性中进行了一项随机、双盲、交叉研究,比较了安慰剂和 ABCC1 抑制剂丙磺舒。在给予盐皮质激素受体拮抗剂钾盐坎利酮和糖皮质激素受体拮抗剂米非司酮(RU486)前后,进行了包括从脂肪和肌肉引流的静脉在内的血液采样。
在安慰剂组中,系统血浆皮质醇和皮质酮浓度在坎利酮后迅速升高。坎利酮+RU486 后,从脂肪中检测到皮质醇摄取,但从肌肉中未检测到。联合受体拮抗后,丙磺舒显著增加了系统皮质醇浓度,且倾向于增加皮质酮和 ACTH 浓度,但对脂肪或肌肉中的净糖皮质激素平衡无影响。在脑库组织中使用定量 PCR,ABCC1 在人脑垂体中的表达是下丘脑和海马的 5 倍,ABCB1 在垂体中的表达高于下丘脑。
尽管丙磺舒对脂肪和骨骼肌中受体的皮质酮和/或皮质醇的置换作用没有足够的精度来检测,但联合受体阻断后,ABCC1 抑制诱导了下丘脑-垂体-肾上腺轴的更大的递增激活,这与 ABCC1 将皮质酮从垂体中输出并增加了 ABC 转运体调节组织糖皮质激素敏感性的证据一致。